At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $1M, lower than 95% of all stocks globally
- PositionOperating margin is -7765.9%, lower than 95% of its Biotechnology peers (median -23.4%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.88BUSDvs all stocks (USD)
Revenue (TTM)
1.00MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.8800xvs all stocks
52-Week Change
2.71%vs all stocks
Market Capitalization
1.88BUSDvs all stocks (USD)
Enterprise Value
1.41BUSDvs all stocks (USD)
Forward P/E
-5.85xvs Biotechnology peers
Price to Book (MRQ)
6.98xvs Biotechnology peers
Enterprise to Revenue
1.41Kxvs Biotechnology peers
Enterprise to EBITDA
-5.13xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-34.42%vs Biotechnology peers
Return on Equity (TTM)
-199.04%vs Biotechnology peers
Revenue (TTM)
1.00MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0190USDUpdated Oct 29, 2026Gross Profit (TTM)
-212.47MUSDvs all stocks (USD)
EBITDA (TTM)
-273.87MUSDvs all stocks (USD)
Net Income (TTM)
-484.38MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-225.97MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-211.39MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
10.00MUSDFY2025 · Dec 31, 2025Operating Income
-211.38MUSDvs all stocks (USD)
Pre-tax Income
-377.82MUSDFY2025 · Dec 31, 2025Income Tax Expense
-79.00KUSDFY2025 · Dec 31, 2025Net Income
-377.74MUSDFY2025 · Dec 31, 2025EBIT
-370.49MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-198.76MUSDFY2025 · Dec 31, 2025Research & Development
168.06MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
53.32MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
12.15MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
7.33MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-377.74MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-182.41MUSDFY2025 · Dec 31, 2025Free Cash Flow
-182.42MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
110.64MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-377.74MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
56.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
26.35MUSDFY2025 · Dec 31, 2025Other Non-cash Items
179.87MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-10.04MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-902.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-18.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-35.00MUSDFY2025 · Dec 31, 2025Purchase of Investments
-417.75MUSDFY2025 · Dec 31, 2025Sale of Investments
200.89MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-216.89MUSDFY2025 · Dec 31, 2025Other Financing Charges
62.34MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
210.91MUSDFY2025 · Dec 31, 2025Shares Outstanding
63.33MSharesUpdated Oct 29, 2026Float Shares
45.02MSharesUpdated Oct 29, 2026Shares Short
11.94MSharesUpdated Oct 29, 2026Short Ratio
18.11daysvs all stocks
Short % of Shares Outstanding
26.90%vs all stocks
% Held by Insiders
19.75%vs all stocks
% Held by Institutions
101.50%vs all stocks
Total Cash (MRQ)
643.13MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
9.87USDUpdated Oct 29, 2026Total Debt (MRQ)
297.86MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.21xvs Biotechnology peers
Current Ratio (MRQ)
9.93xvs Biotechnology peers
Book Value per Share (MRQ)
3.90USDUpdated Oct 29, 2026Total Assets
383.64MUSDvs all stocks (USD)
Total Current Assets
351.17MUSDFY2025 · Dec 31, 2025Total Liabilities
141.50MUSDFY2025 · Dec 31, 2025Total Non-current Assets
32.47MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
78.85MUSDFY2025 · Dec 31, 2025Total Current Liabilities
62.65MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
110.64MUSDFY2025 · Dec 31, 2025Other Short-term Investments
232.55MUSDFY2025 · Dec 31, 2025Accounts Payable
7.11MUSDFY2025 · Dec 31, 2025Short-term Debt
1.11MUSDFY2025 · Dec 31, 2025Long-term Debt
211.00KUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
78.64MUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-765.13MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
242.14MUSDvs all stocks (USD)
52-Week Low
13.50USDUpdated Oct 29, 202652-Week High
44.60USDUpdated Oct 29, 202652-Week Change
2.71%vs all stocks
Beta
-0.8800xvs all stocks
50-Day MA
29.76USDUpdated Oct 29, 2026200-Day MA
24.73USDUpdated Oct 29, 2026Avg 10-Day Volume
496.31KSharesUpdated Oct 29, 2026Avg 30-Day Volume
674.48KSharesUpdated Oct 29, 2026Diluted EPS (TTM)
-9.63USDUpdated Oct 29, 2026Other Income / Expense
-171.25MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -7765.9%, lower than 95% of its Biotechnology peers (median -23.4%)Significant
Operating margin: -77.66Industry median: -0.23Industry P5: -23.37Peers compared: 184
Return on equity is -199%, lower than 95% of its Biotechnology peers (median -22.4%)Significant
Return on equity: -1.99Industry median: -0.22Industry P5: -1.76Peers compared: 184
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.51
Altman Z-Score 2.9: safe zoneNotable
Altman Z-Score: 2.90
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $1M, lower than 95% of all stocks globallySignificant
Revenue (USD): 1,000,000Global P5: 37,231,057.061
Market cap is $1.88B, above the global median of $1.14BNotable
Market cap (USD): 1,875,134,320Global Median: 1,137,180,293.291
Companies that share the same coordination system — how they create, deliver, or capture value.
ABL Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Voronoi, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Mineralys Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Verano Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ascletis Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Mirxes Holding Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Trevi Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cohance Lifesciences Limited
Tier 1ProductionApproval-Gated PipelineRule
Pavella Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
ChemoMetec A/S
Tier 1ProductionApproval-Gated PipelineRule